0      0

AONN+ Annual 2020

FRI04 - Product Theater 1 | Intervening with Jakafi® (ruxolitinib) to Achieve Durable Count Control: Real-World Patient Case Discussion | Focus on Adults with Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea (non-CE) Presentation by Incyte

Nov 6, 2020 10:30am ‐ Nov 6, 2020 11:30am


Key Learning Objectives:

  • Review the clinical and pathophysiological features of polycythemia vera (PV)
  • Describe the characteristics of advanced PV
  • Discuss the pivotal RESPONSE trial of Jakafi® (ruxolitinib) in patients with PV who are resistant to intolerant to hydroxyurea, including primary outcomes, safety, and long-term data
  • Discuss the RESPONSE-2 trial of Jakafi® (ruxolitinib) in patients with PV without splenomegaly, including primary outcomes and safety data
  • Apply clinical concepts to 3 real-world case studies of patients with characteristics of advanced PV


You must be logged in and own this session in order to post comments.